BCMA/CD3 BsAb Therapy for POEMS Syndrome

Exclusion Criteria

• •1. Not meeting the diagnostic criteria for POEMS syndrome, including:
• •* Chronic inflammatory demyelinating polyneuropathy (CIDP),
• •* MGUS, multiple myeloma, amyloidosis, or other plasma cell disorders not meeting POEMS diagnostic criteria.
• •2. History of prior anti-plasma cell therapy, such as melphalan, cyclophosphamide, proteasome inhibitors, IMiDs, monoclonal antibodies, CAR-T, or bispecific antibodies (except:
• •1. Immunosuppressants used for autoimmune neuropathy;
• •2. Bisphosphonates used for bone disease;
• •3. Topical or low-dose steroids ≤20 mg/day for rheumatic disease).
• •3. Investigator judges the patient unsuitable for BCMA/CD3 bispecific therapy (e.g., severe cardiopulmonary dysfunction).
• •4. Known allergy or intolerance to BCMA/CD3 bispecific antibody or any component.